borofalan (10B) 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5422	80994-59-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: borofalan (10B) steboronine boronophenylalanine B-10 SPM-011	Borofalan is a boron compound, namely phenylalanine labeled with 10B (an isotope of boron). Phenylalanine is an amino acid essential for the growth of tumor cells. It has been suggested that the compound accumulatesin tumor cells, mediated by L-type amino acid transporter-1 (LAT-1), an amino acid transporter highly expressed in multiple types of carcinomas including head and neck cancer. Borofalan alone does not inhibit tumor growth, whereas upon irradiation of neutron beams from outside the body, 10B atoms incorporated in tumorcells capture neutrons, resulting in the release of alpha rays and lithium nuclei generated by nuclear reaction, exhibiting a tumor growth-inhibitory effect. Molecular weight: 208.21 Formula: C9H12BNO4 CLOGP: -2.10 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 103.78 ALOGS: -2.54 ROTB: 4

Molecule

Description

Molfile Inchi Smiles

Synonyms:

borofalan (10B)
steboronine
boronophenylalanine B-10
SPM-011

Borofalan is a boron compound, namely phenylalanine labeled with 10B (an isotope of boron). Phenylalanine is an amino acid essential for the growth of tumor cells. It has been suggested that the compound accumulatesin tumor cells, mediated by L-type amino acid transporter-1 (LAT-1), an amino acid transporter highly expressed in multiple types of carcinomas including head and neck cancer. Borofalan alone does not inhibit tumor growth, whereas upon irradiation of neutron beams from outside the body, 10B atoms incorporated in tumorcells capture neutrons, resulting in the release of alpha rays and lithium nuclei generated by nuclear reaction, exhibiting a tumor growth-inhibitory effect.

Molecular weight: 208.21
Formula: C9H12BNO4
CLOGP: -2.10
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 103.78
ALOGS: -2.54
ROTB: 4

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 25, 2020	PMDA	Stella Pharma

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Neoplasm of head and neck	indication	255055008	DOID:11934

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
L-type amino acid transporter 1	Transporter		LAT1_RAT	SUBSTRATE				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D11272	KEGG_DRUG
C5419351	UMLSCUI
53503	PUBCHEM_CID
57659839UA	UNII
UID84303EL	UNII

Pharmaceutical products:

None